DrugPatentWatch Database Preview

Details for Patent: 8,138,195

« Back to Dashboard

Which drugs does patent 8,138,195 protect, and when does it expire?

Patent 8,138,195 protects ZYDELIG and is included in one NDA.

This patent has fifty-three patent family members in twenty-nine countries.

Summary for Patent: 8,138,195

Title:	Inhibitors of human phosphatidylinositol 3-kinase delta
Abstract:	Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K.delta. plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K.delta., while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3K.delta. activity, including compounds that selectively inhibit PI3K.delta. activity. Methods of using PI3K.delta. inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3K.delta. inhibitory compounds to inhibit PI3K.delta.-mediated processes in vitro and in vivo.
Inventor(s):	Sadhu; Chanchal (Bothell, WA), Dick; Kenneth O. (Bothell, WA), Treiberg; Jennifer (Bothell, WA), Sowell; C. Gregory (Mukilteo, WA), Kesicki; Edward A. (Bothell, WA), Oliver; Amy (Bothell, WA)
Assignee:	ICOS Corporation (Bothell, WA)
Application Number:	11/110,204
Patent Claim Types: see list of patent claims	Compound; Use; Composition;

Drugs Protected by US Patent 8,138,195

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-001	Jul 23, 2014		RX	Yes	No			Y	Y		FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-002	Jul 23, 2014		RX	Yes	Yes			Y	Y		FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA

Non-Orange Book US Patents Family Members for Patent 8,138,195

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,487,772	Inhibitors of human phosphatidylinositol 3-kinase delta
8,637,533	Inhibitors of human phosphatidylinositol 3-kinase delta
6,800,620	Inhibitors of human phosphatidylinositol 3-kinase delta
6,949,535	Inhibitors of human phosphatidyl-inositol 3-kinase delta

International Family Members for US Patent 8,138,195

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Denmark	1278748
China	1440408
China	1606444
Cyprus	1116299